SCHEMBL5098164

SCHEMBL5098164

CCSc1nnc(C23CC4CC(CC(C4)C2)C3)n1C(C)C

nearest known ligand 0.43

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 7/20 0.43
MEN1 O00255 4/20 0.38
KMT2A Q03164 4/20 0.38
ALDH1A1 P00352 1/20 0.38
GAA P10253 1/20 0.37
RAB9A P51151 1/20 0.37
MAPK1 P28482 1/20 0.36
TP53 P04637 1/20 0.36
HSD17B1 P14061 1/20 0.35
HPGD P15428 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5104785 0.84 HSD11B1 (0.39) HSD11B1MEN1KMT2AALDH1A1GAA
SCHEMBL5104929 0.81 MEN1 (0.46) HSD11B1MEN1KMT2AALDH1A1GAA
SCHEMBL2667476 0.81 MEN1 (0.53) HSD11B1MEN1KMT2AALDH1A1GAA
SCHEMBL611826 0.79 HSD11B1 (0.58) HSD11B1MEN1KMT2AALDH1A1GAA
SCHEMBL14277202 0.79 HSD11B1 (0.44) HSD11B1MEN1KMT2AALDH1A1GAA
SCHEMBL14277208 0.76 ALDH1A1 (0.45) HSD11B1MEN1KMT2AALDH1A1GAA
SCHEMBL5092243 0.74 HSD11B1 (0.41) HSD11B1MEN1KMT2AGAARAB9A
SCHEMBL5098742 0.74 HSD11B1 (0.41) HSD11B1MEN1KMT2AGAARAB9A
SCHEMBL14277211 0.72 HSD11B1 (0.52) HSD11B1MEN1KMT2AALDH1A1GAA
SCHEMBL5098142 0.72 HSD11B1 (0.39) HSD11B1MEN1KMT2AGAARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7329683-B2 11-β-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia MERCK & CO., INC. (US) 2008-02-12 US disclosed
US-7329683-B2 11-β-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia MERCK & CO., INC. (US) 2008-02-12 US disclosed
US-7329683-B2 11-β-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia MERCK & CO., INC. (US) 2008-02-12 US disclosed
US-20050070720-A1 11-Beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia MERCK SHARP & DOHME CORP. 2005-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070720-A1 11-Beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia HSD11B1, HSD17B1, HSD11B2 HSD11B1 1/4885MEN1 2285/4885KMT2A 2645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.